Mike
- Wells Fargo has initiated coverage of Arcus Biosciences (NYSE:RCUS) with an outperform rating saying that the company’s renal cell carcinoma candidate, casdatifan, has best-in-class potential.
- The firm has a price target of $29 (~66% upside based on Oct. 8 close).
- Analyst
